|
Published by: Global Markets Direct
Published: Jan. 24, 2011 - 59 Pages
Table of Contents- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Arthritis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Arthritis
- Arthritis Therapeutics under Development by Companies
- Arthritis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Companies Involved in Arthritis Therapeutics Development
- Targeted Genetics Corporation
- Cytokine PharmaSciences, Inc.
- Albany Molecular Research, Inc.
- Sylentis
- Daewoong Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Merial Limited
- Compugen Ltd.
- Protalix BioTherapeutics, Inc.
- PLx Pharma Inc.
- Kemin Industries, Inc.
- Universities/Institutes Involved in Arthritis Therapeutics Development
- Arthritis Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Late Stage Drug Profiles - Companies
- Preparation Rich In Growth Factors - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Late Stage Drug Profiles - Universities/Institutes
- Alfacalcidol - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Amitriptyline + Pregabalin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Azithromycin + Rifampin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Botulinum toxin A - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Celecoxib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Celecoxib + Famotidine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Corticosterone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Doxycycline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Doxycycline + Rifampin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Etoricoxib - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Famotidine + Dologesics - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Infliximab + Methotrexate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Naproxen - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Arthritis - Featured News
- Aug 06, 2010: Galapagos Initiates Phase I Study Of GLPG0634 In Arthritis Patients
- Oct 19, 2009: Celgene Corporation Presents Results Of Phase II Trial Study Of Apremilast In Adult Patients With Psoriatic Arthritis
- Feb 09, 2009: Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application For Novel Treatment Of Arthritis Using RPI-78
- Nov 04, 2008: Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Oct 27, 2008: Targeted Genetics Announces Presentation Of Data From Completed Phase I/II Trial Of tgAAC94 At American College Of Rheumatology
- Jun 12, 2008: Targeted Genetics Announces Positive Phase I/II tgAAC94 Data Presented At Annual European Congress Of Rheumatology
- Mar 18, 2008: Targeted Genetics Announces Completion Of Dosing For The Phase I/II Clinical Trial Of tgAAC94 For Inflammatory Arthritis
- Dec 03, 2007: Targeted Genetics Reports On Recombinant DNA Advisory Committee (RAC) Assessment Of Its Phase I/II Trial Of tgAAC94 For Inflammatory Arthritis
- Nov 26, 2007: Targeted Genetics Announces That FDA Has Removed Hold On Phase I/II Clinical Trial Of tgAAC94 For Inflammatory Arthritis
- Nov 10, 2007: Targeted Genetics Announces Positive Interim Phase I/II Results For tgAAC94 In Inflammatory Arthritis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Arthritis, 2011
- Products under Development for Arthritis - Comparative Analysis, 2011
- Comparative Analysis by Late Stage Development, 2011
- Comparative Analysis by Mid Clinical Stage Development, 2011
- Comparative Analysis by Early Clinical Stage Development, 2011
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
- Targeted Genetics Corporation, 2011
- Cytokine PharmaSciences, Inc., 2011
- Albany Molecular Research, Inc., 2011
- Sylentis, 2011
- Daewoong Pharmaceutical Co., Ltd., 2011
- Pfizer Inc., 2011
- Merial Limited, 2011
- Compugen Ltd., 2011
- Protalix BioTherapeutics, Inc., 2011
- PLx Pharma Inc., 2011
- Kemin Industries, Inc., 2011
- Assessment by Monotherapy Products, 2011
- Assessment by Combination Products
- Assessment by Stage and Route of Administration, 2011
- Assessment by Molecule Type, 2011
- List of Figures
- Number of Products under Development for Arthritis, 2011
- Products under Development for Arthritis - Comparative Analysis, 2011
- Products under Development by Companies, 2011
- Products under Investigation by Universities/Institutes, 2011
- Late Stage Products, 2011
- Mid Clinical Stage Products, 2011
- Early Clinical Stage Products, 2011
- Discovery and Pre-Clinical Stage Products, 2011
- Assessment by Monotherapy Products, 2011
- Assessment by Combination Products, 2011
- Assessment by Route of Administration, 2011
- Assessment by Stage and Route of Administration, 2011
- Assessment by Molecule Type, 2011
- Assessment by Stage and Molecule Type, 2011
AbstractArthritis - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Arthritis - Pipeline Review, Q1 2011', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arthritis. 'Arthritis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope- A snapshot of the global therapeutic scenario for Arthritis.
- A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Arthritis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Arthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
